CTOs on the Move

Atomwise

www.atomwise.com

 
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.atomwise.com
  • 717 Market Street Suite 800
    San Francisco, CA USA 94103
  • Phone: 650.720.8923

Executives

Name Title Contact Details

Funding

Atomwise raised $45M on 03/07/2018
Atomwise raised $123M on 08/11/2020

Similar Companies

Becton Dickinson and Company

Becton Dickinson and Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SyntheZyme

SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how

Ceregene

Ceregene is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedXcel

MedXcel is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenxbio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.